Literature DB >> 25275435

Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men.

M Xiridou1, L C Soetens1, F D H Koedijk1, M A B VAN DER Sande1, J Wallinga1.   

Abstract

Gonorrhoea is one of the most common sexually transmitted infections. The control of gonorrhoea is extremely challenging because of the repeated development of resistance to the antibiotics used for its treatment. We explored different strategies to control the spread of antimicrobial resistance and prevent increases in gonorrhoea prevalence. We used a mathematical model that describes gonorrhoea transmission among men who have sex with men and distinguishes gonorrhoea strains sensitive or resistant to three antibiotics. We investigated the impact of combination therapy, switching first-line antibiotics according to resistance thresholds, and other control efforts (reduced sexual risk behaviour, increased treatment rate). Combination therapy can delay the spread of resistance better than using the 5% resistance threshold. Increased treatment rates, expected to enhance gonorrhoea control, may reduce gonorrhoea prevalence only in the short term, but could lead to more resistance and higher prevalence in the long term. Re-treatment of resistant cases with alternative antibiotics can substantially delay the spread of resistance. In conclusion, combination therapy and re-treatment of resistant cases with alternative antibiotics could be the most effective strategies to prevent increases in gonorrhoea prevalence due to antimicrobial resistance.

Entities:  

Keywords:  men who have sex with men

Mesh:

Substances:

Year:  2014        PMID: 25275435      PMCID: PMC9507228          DOI: 10.1017/S0950268814002519

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  30 in total

1.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions.

Authors:  M Lipsitch; C T Bergstrom; B R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis.

Authors:  J-J Parienti; V Cattoir; P Thibon; G Lebouvier; R Verdon; C Daubin; D du Cheyron; R Leclercq; P Charbonneau
Journal:  J Hosp Infect       Date:  2011-04-16       Impact factor: 3.926

3.  Evaluating treatment protocols to prevent antibiotic resistance.

Authors:  S Bonhoeffer; M Lipsitch; B R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval.

Authors:  Takashi Deguchi; Mitsuru Yasuda; Shigeaki Yokoi; Ken-Ichiro Ishida; Masayasu Ito; Satoshi Ishihara; Ken Minamidate; Yoshimasa Harada; Kanhin Tei; Kentaro Kojima; Masayoshi Tamaki; Shin-Ichi Maeda
Journal:  J Infect Chemother       Date:  2003-03       Impact factor: 2.211

5.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey.

Authors:  G P Garnett; K J Mertz; L Finelli; W C Levine; M E St Louis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

7.  The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption.

Authors:  D J Austin; M Kakehashi; R M Anderson
Journal:  Proc Biol Sci       Date:  1997-11-22       Impact factor: 5.349

8.  The impact of the phase of an epidemic of sexually transmitted infection on the evolution of the organism.

Authors:  K M E Turner; G P Garnett
Journal:  Sex Transm Infect       Date:  2002-04       Impact factor: 3.519

9.  Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain.

Authors:  Jordi Cámara; Judit Serra; Josefina Ayats; Teresa Bastida; Dolors Carnicer-Pont; Antònia Andreu; Carmen Ardanuy
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

10.  Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards.

Authors:  Roger D Kouyos; Pia Abel Zur Wiesch; Sebastian Bonhoeffer
Journal:  PLoS Comput Biol       Date:  2011-03-03       Impact factor: 4.475

View more
  13 in total

Review 1.  Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling.

Authors:  Yonatan H Grad; Edward Goldstein; Marc Lipsitch; Peter J White
Journal:  J Infect Dis       Date:  2015-10-30       Impact factor: 5.226

2.  Application of dynamic modelling techniques to the problem of antibacterial use and resistance: a scoping review.

Authors:  D E Ramsay; J Invik; S L Checkley; S P Gow; N D Osgood; C L Waldner
Journal:  Epidemiol Infect       Date:  2018-07-31       Impact factor: 4.434

3.  Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study.

Authors:  Stephanie M Fingerhuth; Nicola Low; Sebastian Bonhoeffer; Christian L Althaus
Journal:  BMC Med       Date:  2017-07-26       Impact factor: 8.775

4.  A comprehensive overview of urogenital, anorectal and oropharyngeal Neisseria gonorrhoeae testing and diagnoses among different STI care providers: a cross-sectional study.

Authors:  Casper D J den Heijer; Christian J P A Hoebe; Geneviève A F S van Liere; Jan E A M van Bergen; Jochen W L Cals; Frans S Stals; Nicole H T M Dukers-Muijrers
Journal:  BMC Infect Dis       Date:  2017-04-20       Impact factor: 3.090

5.  Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies.

Authors:  Burcu Tepekule; Hildegard Uecker; Isabel Derungs; Antoine Frenoy; Sebastian Bonhoeffer
Journal:  PLoS Comput Biol       Date:  2017-09-15       Impact factor: 4.475

6.  Test of cure, retesting and extragenital testing practices for Chlamydia trachomatis and Neisseria gonorrhoeae among general practitioners in different socioeconomic status areas: A retrospective cohort study, 2011-2016.

Authors:  Juliën N A P Wijers; Geneviève A F S van Liere; Christian J P A Hoebe; Jochen W L Cals; Petra F G Wolffs; Nicole H T M Dukers-Muijrers
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

7.  Population-level mathematical modeling of antimicrobial resistance: a systematic review.

Authors:  Anna Maria Niewiadomska; Bamini Jayabalasingham; Jessica C Seidman; Lander Willem; Bryan Grenfell; David Spiro; Cecile Viboud
Journal:  BMC Med       Date:  2019-04-24       Impact factor: 8.775

8.  What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion.

Authors:  Nicole H T M Dukers-Muijrers; Julius Schachter; Genevieve A F S van Liere; Petra F G Wolffs; Christian J P A Hoebe
Journal:  BMC Infect Dis       Date:  2015-11-17       Impact factor: 3.090

9.  Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners.

Authors:  Stephanie M Fingerhuth; Sebastian Bonhoeffer; Nicola Low; Christian L Althaus
Journal:  PLoS Pathog       Date:  2016-05-19       Impact factor: 6.823

10.  Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhea.

Authors:  Ashleigh R Tuite; Thomas L Gift; Harrell W Chesson; Katherine Hsu; Joshua A Salomon; Yonatan H Grad
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.